PepGen, Inc. announced a critical clinical milestone for PGN-EDO51, the company’s lead product candidate for the treatment of Duchenne muscular dystrophy patients whose mutations are amenable to an exon 51 skipping approach.
[PepGen, Inc.]
6445212
nan
items
1
apa
0
default
asc
1
173872
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
